Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Insulin therapy is ultimately necessary for the control of blood glucose in a majority of patients with type 2 diabetes mellitus. Unfortunately, the pharmacokinetic characteristics of previously available rapid-, intermediate-, and long-acting preparations make sustained normoglycemia almost impossible. Advances in molecular genetic engineering have made possible the development of insulin analogues with pharmacokinetics that more closely mimic the needs of patients with type 2 diabetes. In the following article, we explore the insulin analogues currently available for clinical use, their pharmacokinetics, and the rationale for their use in the treatment of type 2 diabetes, and follow-up with a brief examination of future developments.

Type

Journal article

Journal

Curr Diab Rep

Publication Date

10/2002

Volume

2

Pages

403 - 408

Keywords

Administration, Inhalation, Administration, Oral, Carrier Proteins, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Insulin Aspart, Insulin Detemir, Insulin Glargine, Insulin Lispro, Insulin, Long-Acting